Dermatology

Lung Cancer

Questions discussed in this category

How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?

Should we switch to a new TKI?

1 Answer available

Papers discussed in this category

Current oncology (Toronto, Ont.), 2015 Apr

Management of egfr tki-induced dermatologic adverse events.

Related Topics in Dermatology